Loratadine

CHEMBL998 Phase 4 Aprovado Small molecule
Half-Life
8 hours
Bioavailability
Protein Binding
Molecular Weight
382.9 g/mol
LogP
5.2
Phase
4

A second-generation, non-sedating antihistamine, loratadine blocks peripheral H1 histamine receptors to reduce sneezing, runny nose, and itching without causing significant drowsiness. It treats allergic rhinitis and chronic hives. Sold over the counter as Claritin and Alavert, the compound has the formula C22H23ClN2O2 and its minimal central nervous system penetration distinguishes it from older allergy medications.

A second-generation, non-sedating antihistamine used to relieve allergic rhinitis and hives (urticaria). It blocks peripheral H1 histamine receptors to reduce sneezing, runny nose, and itching without causing significant drowsiness.

Peso Molecular

382,8800 g/mol

LogP

5,20

TPSA

42,40 Ų

Regra dos 5 de Lipinski

Aprovado

Classes de Medicamentos

Mecanismo de Ação

Second-generation H1 antihistamine with minimal CNS effects.

Pharmacokinetics (PK)

Half-Life 8 hours

Pharmacodynamics (PD)

Mecanismo

Second-generation H1 antihistamine with minimal CNS effects.

Estrutura 2D

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

CCOC(=O)N1CCC(=C2c3ccc(Cl)cc3CCc3cccnc32)CC1

InChI

InChI=1S/C22H23ClN2O2/c1-2-27-22(26)25-12-9-15(10-13-25)20-19-8-7-18(23)14-17(19)6-5-16-4-3-11-24-21(16)20/h3-4,7-8,11,14H,2,5-6,9-10,12-13H2,1H3

Molecular Formula

C22H23ClN2O2

HBD / HBA

- / 3

Ligações Rotacionáveis

2

Átomos Pesados

27

Primary Target

No side effects recorded

Side effect data is not yet available for this drug.

Perguntas frequentes

A second-generation, non-sedating antihistamine used to relieve allergic rhinitis and hives (urticaria). It blocks peripheral H1 histamine receptors to reduce sneezing, runny nose, and itching without causing significant drowsiness.

Second-generation H1 antihistamine with minimal CNS effects.

Key pharmacokinetic parameters for Loratadine: Half-life: 8 hours.

Yes, Loratadine is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

Related Drugs

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL998. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 3957. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Aviso Médico

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.